🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525574-19-00
Authorised Phase I

A Study of Long-Term Safety, Tolerability, and Clinical Outcomes of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis: A Multicenter, Open-Label, Long-Term Extension of Study J6I-MC-OWAA

2026-525574-19-00 · tracked via the Priya Life Science EU tracker
Sponsor
Eli Lilly & Co.
Sponsor type
Pharmaceutical company
Therapeutic area
Nervous System Diseases
Decision date
22/09/2026
Enrollment target
10
Sites
Netherlands, Germany

Condition studied

Amyotrophic Lateral Sclerosis

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525574-19-00 on CTIS ↗ ← All trials in the EU